

Attorney Docket : ANVIL.001BNP2
Appl. No. : Unknown
Filed : Herewith

AMENDMENTS TO THE CLAIMS

1. **(Original)** A prosthesis and deployment catheter system for treating an opening from a main body lumen to a branch body lumen, the prosthesis comprising:

a radially expansible support, the support configured to be deployed in at least a portion of the branch body lumen;

a plurality of fronds extending axially from an end of the support and configured to be positioned across the Os and into the main body lumen; and

at least one circumferential link connecting at least a first and a second frond, the circumferential link spaced axially apart from the support;

wherein the prosthesis is mounted on a balloon catheter such that the radially expansible support is carried by a first portion of a balloon that is inflatable to a first diameter and the circumferential link is carried by a second portion of a balloon that is inflatable to a second diameter that is larger than the first diameter.

2. **(Original)** The system of Claim 1, wherein the circumferential link connects each of the plurality of fronds.

3. **(Original)** The system of Claim 1, wherein the plurality of fronds includes at least three fronds.

4. **(Original)** The system of Claim 1, wherein the balloon catheter comprises a single, stepped balloon having a proximal section with a larger inflated diameter than an inflated diameter of a distal section.

5. **(Original)** The system as in Claim 4, wherein at least a portion of the radially expansible support comprises a drug coating, and at least a portion of the fronds and the circumferential link are without a drug coating.

Attorney Docket : ANVIL.001BNP2
Appl. No. : Unknown
Filed : Herewith

6. **(Original)** The system of Claim 5, wherein the drug coating is configured to produce at least one of a controlled drug release rate, a constant drug release rate, bi-modal drug release rate or a controlled concentration of drug proximate a target vessel wall.

7. **(Original)** The system of Claim 5, wherein the drug is one of an anti-cell proliferative, anti cell migration, anti-neo plastic, anti inflammatory drug.

8. **(Original)** The system of Claim 5, wherein the drug is configured to reduce an incidence or amount of restenosis.

9. **(Original)** The system of Claim 5, wherein the drug includes a first drug and second a drug.

10. **(Original)** The system of Claim 5, wherein the drug coating includes a first coating and a second coating.

11. **(Original)** The system of Claim 10, wherein the first coating is configured to produce a first drug release rate and the second coating is configured to produce a second drug release rate.

12.-29. **(Canceled)**